KoBioLabs, Inc (KOSDAQ:348150)
5,440.00
-510.00 (-8.57%)
At close: Apr 2, 2026
KoBioLabs Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -6,330 | -5,298 | -13,853 | -21,921 | -15,382 |
Depreciation & Amortization | 2,777 | 2,578 | 1,515 | 908.06 | 232.72 |
Loss (Gain) From Sale of Assets | - | 123.43 | - | 6.85 | - |
Loss (Gain) From Sale of Investments | -191.75 | - | - | -11.51 | -7.33 |
Stock-Based Compensation | 190.7 | 265.42 | 800.35 | 1,695 | 1,571 |
Other Operating Activities | -343.23 | 942.99 | -2,408 | 3,127 | -704.12 |
Change in Accounts Receivable | -1,203 | -950.57 | -1,266 | -702.54 | 2,478 |
Change in Inventory | -1,040 | -3,202 | -487.87 | -725.03 | -150.65 |
Change in Accounts Payable | -1.25 | 2.62 | - | - | - |
Change in Unearned Revenue | - | -5.45 | -114.78 | -512.29 | 361.64 |
Change in Other Net Operating Assets | 356.78 | 1,188 | 1,982 | 1,580 | -880.97 |
Operating Cash Flow | -5,784 | -4,355 | -13,832 | -16,556 | -12,481 |
Capital Expenditures | -296.78 | -1,640 | -15,133 | -14,683 | -5,512 |
Sale of Property, Plant & Equipment | - | 1.21 | 0.81 | - | - |
Sale (Purchase) of Intangibles | -256.13 | -6.5 | -428.32 | -81.81 | -39.07 |
Investment in Securities | 10,138 | 6,113 | 23,960 | -46,421 | -25,454 |
Other Investing Activities | -137.03 | 1,967 | -217.46 | -748.86 | -19.09 |
Investing Cash Flow | 9,448 | 6,434 | 8,192 | -61,814 | -31,154 |
Short-Term Debt Issued | 6,800 | 4,800 | - | - | - |
Long-Term Debt Issued | 3,500 | 3,200 | 4,000 | 6,059 | 13,346 |
Total Debt Issued | 10,300 | 8,000 | 4,000 | 6,059 | 13,346 |
Short-Term Debt Repaid | -4,500 | -1,075 | - | - | - |
Long-Term Debt Repaid | -9,298 | -13,582 | -339.15 | -95.54 | -39.3 |
Total Debt Repaid | -13,798 | -14,657 | -339.15 | -95.54 | -39.3 |
Net Debt Issued (Repaid) | -3,498 | -6,657 | 3,661 | 5,964 | 13,307 |
Issuance of Common Stock | 112.75 | 151.32 | 395.17 | 10,750 | 4,350 |
Other Financing Activities | 0 | -7.48 | -9.89 | 19,596 | -0 |
Financing Cash Flow | -3,386 | -6,513 | 4,046 | 36,310 | 55,741 |
Foreign Exchange Rate Adjustments | -1,373 | 76.26 | 1,208 | -199.67 | -40.36 |
Net Cash Flow | -1,095 | -4,358 | -386.23 | -42,260 | 12,066 |
Free Cash Flow | -6,081 | -5,995 | -28,966 | -31,239 | -17,993 |
Free Cash Flow Margin | -8.78% | -8.77% | -87.41% | -269.17% | -621.88% |
Free Cash Flow Per Share | -313.19 | -312.34 | -1563.45 | -1859.88 | -1121.36 |
Cash Interest Paid | 532.41 | 670.65 | 303.02 | 140.63 | 8.88 |
Cash Income Tax Paid | -154.06 | 15.9 | 249.35 | 239.81 | 180.4 |
Levered Free Cash Flow | -6,010 | -11,457 | -20,874 | -24,552 | -16,000 |
Unlevered Free Cash Flow | -5,689 | -10,733 | -19,916 | -23,501 | -15,904 |
Change in Working Capital | -1,887 | -2,967 | 113.36 | -359.91 | 1,808 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.